PSA Decrease with Fulvestrant Acetate in a Hormone-Resistant Metastatic Prostate Cancer Patient: A Case Report

Metastatic prostate cancer is an incurable disease. After a period of hormone sensitivity that allows for the use of antiandrogens, the disease invariably progresses to a situation of androgen-independent growth, which deserves the consideration or the use of chemotherapy. As many of these patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Gasent Blesa, Joan Manel, Alberola Candel, Vicente
Formato: Texto
Lenguaje:English
Publicado: S. Karger AG 2009
Materias:
Published: April, 2009
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2918833/
https://www.ncbi.nlm.nih.gov/pubmed/20740149
http://dx.doi.org/10.1159/000214838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2918833/
https://www.ncbi.nlm.nih.gov/pubmed/20740149
http://dx.doi.org/10.1159/000214838

Ejemplares similares